ACR Efficacy Data in PsA | TREMFYA® (guselkumab) HCP

IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
ACR RESPONSE RATES IN DISCOVER 1 AND DISCOVER 2

Over 50% of Patients Achieved ACR20 Response at Week 24, After Just 4 Injections1,2

View Study Design

DISCOVER 2: ACR20, ACR50, AND ACR70 RESPONSES AT WEEK 24 (NONRESPONDER IMPUTATION [NRI])*

ACR50 response and ACR70 response at Week 24 were not part of the sequential testing procedure but were prespecified to be tested upon achieving statistical significance for ACR20 response.

*Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent due to any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
Patients with missing data were considered nonresponders.

View Study Design

DISCOVER 1: ACR20, ACR50, AND ACR70 RESPONSES AT WEEK 24 (NRI)*

ACR50 response and ACR70 response at Week 24 were not part of the sequential testing procedure but were prespecified to be tested upon achieving statistical significance for ACR20 response.

*Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent due to any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
Patients with missing data were considered nonresponders.
NS=not significant.

References: 1. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30263):1-11. 2. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30265):1-11.